FDA approves new updated COVID-19 vaccines to target KP.2 variant. Here's what to know

The newly approved formulations of COVID-19 vaccines by the FDA are specifically designed to target the prevalent KP.2 strain, which accounts for approximately 70% of recent U.S. infections.

As COVID-19 infections are increasing across numerous states, the new vaccines provide a timely intervention for curbing the spread, especially benefiting vulnerable populations.

The ongoing rise in COVID-19 cases highlights the necessity of updated vaccines, as waning immunity from prior vaccinations calls for renewed defensive measures.

The FDA suggests that like seasonal flu vaccines, COVID-19 vaccines may require annual updates to combat emerging variants and to ensure sustained effectiveness.

Read at Fast Company